Impact of the Sustained Viral Response of Chronic Hepatitis c After Treatment With Direct Action Antivirals
Study Details
Study Description
Brief Summary
The purpose of this study is to evaluate the evolution of liver injury with fibrosis data obtained using non-invasive serological markers in patients who achieved SVR after treatment with direct-acting antivirals.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Detailed Description
This open study includes patients with chronic hepatitis C who received treatment with the new direct-acting antivirals between November 1, 2014 and December 31, 2017, who achieved a sustained viral response at week 12.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| cases Patients treated with direct-acting antivirals. |
Outcome Measures
Primary Outcome Measures
- Number of patients with a progression of liver injury. [Up to 4 weeks]
To assess the evolution of liver injury with fibrosis data in patients who achieved SVR after treatment with direct-acting antivirals.
Secondary Outcome Measures
- Identify patients who develop liver-related events (liver decompensation, hepatocellular carcinoma, and death) after achieving sustained viral response. [Up to 4 weeks.]
Development of hepatic decompensation, defined as a patient with ascites, spontaneous bacterial peritonitis (PBR), digestive bleeding of varicose origin, or hepatic encephalopathy at some point in the evolution from SVR until the end of study follow-up.
- Rate of risk factors presented by patients. [Up to 4 weeks.]
Identify risk factors in patients who develop liver complications after achieving sustained viral response.
- Absence of improvement in non-invasive fibrosis parameters vs the development of liver complications. [Up to 4 weeks.]
To determine if there is a relationship between the absence of improvement in non-invasive fibrosis parameters and the development of liver complications.
- Clinical and fibrosis data. [Up to 4 weeks.]
To compare the clinical and fibrosis data between patients who develop liver complications and those who do not.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients with chronic liver disease caused by virus C.
-
Have received treatment with the new DAAs between November 1, 2014 and December 1,
- Patients diagnosed with advanced fibrosis and liver cirrhosis. Advanced fibrosis was defined as a Fibroscan> 10 kPa, an APRI index> 1.5 and / or a FIB-4 index> 3.25. For its part, cirrhosis was defined such as a Fibroscan> 12.5 kPa and / or presence of esophagogastric varices in the endoscopic study and / or data portal hypertension ultrasound.
Exclusion Criteria:
-
Coinfection by virus B or HIV.
-
Development of HCC before or during treatment.
-
Abuse of alcohol intake or addiction to parenteral drugs.
-
Liver disease of non-viral etiology (autoimmune, toxic, metabolic).
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Hospital Universitario Virgen macarena | Sevilla | Spain | 41009 |
Sponsors and Collaborators
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Investigators
- Principal Investigator: Paula Fernández Álvarez, Hospital Universitario Virgen Macarena
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- FIS-ANT- 2021-01